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The patient is a 61-year-old male never smoker who ﬁrst presented with pain in his left hip and right-sided chest 
pain in 2014. Imaging revealed lytic bone lesions in the left 
iliac wing, right sixth rib, left eleventh rib, and T12. Core 
biopsy was performed on the left iliac wing, and it revealed 
CK7+, TTF1+, and vimentin+ sarcomatoid non–small-cell 
lung cancer. Comprehensive genomic proﬁling was per-
formed through FoundationOne (Foundation Medicine, Inc., 
Cambridge, MA) on the pretreatment biopsy specimen, and 
the tumor harbored two MET alterations predicted to result 
in skipping of exon 14 (c.2888-5_2890TTAAGATC>A and 
c.3028+2T>G) and a known activating point mutation in MET 
(p.H1094Y, c.3280C>T).
The patient was treated with radiation to painful bony 
lesions followed by carboplatin, paclitaxel, and bevacizumab 
on the ECOG5508 trial (NCT01107626). Although there was 
some evidence for response after two cycles, he experienced 
clear progressive disease after four cycles and MET-directed 
therapy was considered.
Skipping of exon 14 deletes a region of the juxtamem-
brane domain causing a decreased rate of MET degradation. 
Mutations leading to MET exon 14 skipping have previously 
been reported including responses to MET inhibitors.1–3 In 
light of the multiple MET alterations observed in the patient 
including an activating mutation, he was treated on a clini-
cal trial of the MET inhibitor crizotinib (NCT00585195). 
He experienced a partial response by Response Evaluation 
Criteria in Solid Tumors 1.0 criteria, which was accompanied 
by the patient reporting symptomatic improvement in activ-
ity level and pain. Most notably, a dominant right-sided chest 
mass decreased from 8.2 to 6.1 cm, but there was no clear 
change in bony lesions (Fig. 1). This lasted for more than 5 
months until he experienced progressive pain. Imaging con-
ﬁrmed progression both in the lung and in bony lesions. The 
patient is now on hospice care.
This case illustrates the potential of comprehensive 
genomic proﬁling to identify mutations that are actionable on 
clinical trials and the potential activity of crizotinib against 
MET exon 14 splice site mutations, a hypothesis being tested 
by ongoing studies (NCT00585195). Such ﬁndings will be 
applicable to a sizable group of patients—MET mutations 
have been estimated to occur in 3% of squamous cell cancers 
of the lung4 and 3–8% of adenocarcinomas of the lung1,5 as 
well as in other lung neoplasms, brain gliomas, and cancers of 
unknown primary.1
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fIGURE 1. Pre- and post treatment CT scans.
